Express Mail Label No. EL 789 848 704 US

PATENT

Date of Deposit is January 3, 2002
I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box: Patent Application, Washington, D. C. 20231.

Atty. Docket No. DX0589K1B

CN 028008

By: Lois E. Miller, January 3, 2002 date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Wang, et al.	Examiner:	not yet assigned
Serial No.:	Divisional of 08/887,977	Art Unit:	not yet assigned
Filed:	Herewith	PRELIMINARY AMENDMENT	
Title:	MAMMALIAN CHEMOKINE REAGENTS	January 3, 2002	

Assistant Commissioner for Patents
Box: Patent Application
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Honorable Sir:

Applicants submit the following preliminary amendment. Applicants request entry of the following amendments prior to examination of the application. Accompanying this amendment is a copy of a Restriction Requirement, dated August 20, 1999, made by the Examiner for the parent application USSN 08/887,977, filed July 3, 1997.

IN THE CLAIMS:

Please cancel claims 1-22, without prejudice.

Please add new claims 23-42 as indicated below.

23. (New) A substantially pure or isolated polypeptide comprising SEQ ID NO:2 or 4, or an antigenic fragment thereof.

24. (New) The polypeptide of Claim 23, wherein the polypeptide is detectably labeled.

25. (New) The polypeptide of Claim 23, wherein the polypeptide is attached to a solid substrate.

26. (New) The polypeptide of Claim 23, wherein the polypeptide is a fusion protein.

27. (New) An isolated polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4, or an antigenic polypeptide thereof.

28. (New) The polynucleotide of Claim 27, wherein the polynucleotide is detectably labeled.

29. (New) The polynucleotide of Claim 27, wherein the polynucleotide is a PCR product.

30. (New) An expression vector comprising the polynucleotide of Claim 27.

31. (New) A host cell comprising the expression vector of Claim 30.

32. (New) A method of producing a polypeptide of SEQ ID NO:2 or 4 comprising:

a) culturing the host cell of Claim 31 under conditions suitable for expression of the polypeptide; and

b) isolating or purifying the polypeptide.

33. (New) An antigen binding composition which binds to a polypeptide of Claim 23.

34. (New) The antigen binding composition of Claim 33, wherein the binding composition is an Fv, Fab, or Fab2 antibody fragment.

35. (New) The antigen binding composition of Claim 33, wherein the antigen binding composition is an antibody.

36. (New) The antibody of Claim 35 wherein the antibody is:

a) a monoclonal antibody;

b) a polyclonal antibody.

37. (New) The antibody of Claim 35, wherein the antibody is attached to a solid substrate.

38. (New) The antibody of Claim 35, wherein the antibody is detectably labeled.

39. (New) A method of modulating physiology or development of a cell expressing a receptor for the polypeptide of Claim 23 comprising contacting the cell with an agonist or antagonist of the polypeptide.

40. (New) The method of Claim 39, wherein the cell is a macrophage or a lymphocyte.

41. (New) The method of Claim 39, wherein the antagonist is an antibody which binds to the polypeptide.

42. (New) The method of Claim 39, wherein the physiology is selected from the group consisting of:

a) a cellular calcium flux;

b) a chemoattractant response;

c) cellular morphology modification responses;

d) phosphoinositide lipid turnover; and

e) an antiviral response.

REMARKS

Applicants cancel originally filed Claims 1-22, without prejudice. New claims 23-42 are added. Support for new Claims 23-26 can be found in originally filed Claim 3. New Claims 27-32 are supported by originally filed Claims 4-6. Support for new Claims 33-38 can be found in originally filed Claim 15. Support for new Claims 39-42 can be found in originally filed Claims 19-21. Applicants believe that no new matter is added by the above amendments. Entry of the above amendment is therefore respectfully requested.

Applicants believe that no further fees are required by the above amendment. Should this not be the case, the Commissioner is hereby authorized to debit any fees or credit any overpayments to DNAX Research Institute Deposit Account No. **04-1239**.

Respectfully submitted,

Date: January 3, 2002

Sheela Mohan-Peterson
Reg. No. 41,201
Attorney for Applicants

DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
TEL: 650-496-1244
FAX: 650-496-1200